Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

WuXi AppTec increases revenue by 56.9% and raises earnings per share to $0.33

WuXi AppTec released results for the quarter ended June 30, 2026: revenue rose to $2.42 billion, an increase of 56.96% year over year. Earnings per share increased to $0.33 from $0.23 in the same quarter last year. » More on finanzen.net
WuXi AppTec raises annual guidance after strong first half

WuXi AppTec shares rose 10.7% to HK$180.3 after strong H1 figures: revenue of about RMB 28.9bn (+38.9%) and net profit attributable to shareholders of RMB 11.08bn (+33.7%), well above the Bloomberg consensus. On an adjusted non‑IFRS basis net profit grew 83.2%. The company raised its full‑year revenue forecast and announced an interim dividend of RMB 5.1 per 10 shares; CEO Li Ge cited demand from weight‑loss and diabetes programs and gains in the US business as drivers. » More on de.investing.com
WuXi AppTec recovers after US sanctions list thanks to analyst praise and share buyback

WuXi AppTec’s H-share rose 3.3% to HK$120.6 after having fallen sharply earlier following inclusion on the US-1260H list. JPMorgan confirmed an “Overweight” rating with a HK$172 target and criticized the Pentagon designation as flawed. WuXi announced a board-approved buyback program for A-shares to fund an employee equity scheme and said it will pursue legal action against the listing. The regulatory overhang from 1260H remains a key risk, but investors are currently pricing in the company’s strong fundamentals and the management signal. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, WuXi AppTec H has already paid €0.26 in dividends. The last payout was in September.

Financials

In the last quarter, WuXi AppTec H had revenue of €2.19B and net profit of €1.1B

(EUR)	September 2026	YoY
Revenue	2.19B	52.03%
Gross profit	1.2B	67.15%
Net profit	1.1B	160.34%
EBITDA	1.39B	132.27%

Fundamentals

Metric	Value
Market capitalization	€60.51B
Number of shares	2.74B
52-week high/low	€24.96 - €11.01
Dividend yield	1.17%
Dividends TTM	€0.26
Beta	1.12
P/E ratio	16.01
PEG ratio	0.22
P/B ratio	4.41
P/S ratio	7.67

Company profile

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Name	WuXi AppTec H
CEO	Ge Li
Headquarters	Shanghai, sh China
Website	wuxiapptec.com
Sector	Health Care
Industry	Health Care Providers & Services
IPO	12/13/2018
Employees	33,834